Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 19/20 | 0.59 |
| ▸ | FPR2 | P25090 | 2/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25241472 | 0.94 | NPC1 (0.51) | SCN9AFPR2PLA2G2A | |
| SCHEMBL30405699 | 0.94 | NPC1 (0.51) | SCN9AFPR2PLA2G2A | |
| SCHEMBL792486 | 0.92 | NPC1 (0.50) | SCN9AFPR2PLA2G2A | |
| SCHEMBL3134572 | 0.86 | PLA2G2A (0.57) | SCN9AFPR2PLA2G2A | |
| SCHEMBL15383820 | 0.85 | PLA2G2A (0.58) | PLA2G2A | |
| SCHEMBL805905 | 0.85 | SCN9A (0.67) | SCN9AFPR2 | |
| SCHEMBL364073 | 0.82 | SCN9A (0.50) | SCN9AFPR2PLA2G2A | |
| SCHEMBL369039 | 0.82 | SCN9A (0.77) | SCN9A | |
| SCHEMBL369038 | 0.82 | SCN9A (0.77) | SCN9A | |
| SCHEMBL25299294 | 0.81 | SMN1; SMN2 (0.52) | SCN9AFPR2PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3590925-B1 | PYRIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-2616441-B1 | PYRIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-2616441-B1 | PYRIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2019-08-07 | — | — | EP | disclosed |
| US-9765029-B2 | Pyridine compounds as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765029-B2 | Pyridine compounds as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765029-B2 | Pyridine compounds as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9611222-B2 | Pyridine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611222-B2 | Pyridine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20150344465-A1 | PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-12-03 | — | — | US | disclosed |
| US-20150344465-A1 | PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-12-03 | — | — | US | disclosed |
| US-20130345211-A1 | Pyridine Compounds as Sodium Channel Blockers | PURDUE PHARMA L.P. (US) | 2013-12-26 | — | — | US | disclosed |
| US-20130303526-A1 | Pyridine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303526-A1 | Pyridine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303526-A1 | Pyridine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2013-11-14 | — | — | US | disclosed |
| EP-2616441-A2 | PYRIDINE COMPOUNDS AND THE USES THEREOF | Purdue Pharma LP (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-2593434-A1 | PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | Purdue Pharma LP (US) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012035421-A2 | PYRIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012035421-A2 | PYRIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012007836-A1 | PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA .LP. (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007836-A1 | PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA .LP. (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345211-A1 | Pyridine Compounds as Sodium Channel Blockers | SCN1B, CACNA1A, TRPV1 | SCN9A 98/4885FPR2 1837/4885PLA2G2A 628/4885 |
| US-20130303526-A1 | Pyridine Compounds and the Uses Thereof | TRPV1, CACNA1A, KCNA1 | SCN9A 148/4885FPR2 852/4885PLA2G2A 345/4885 |
| US-20150344465-A1 | PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | SCN1B, CACNA1A, SCN1A | SCN9A 96/4885FPR2 2070/4885PLA2G2A 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.